An Integrated Management Model of Patients With Atrial Fibrillation: The Experience of the Local Health Unit Tuscany North-West
DOI:
https://doi.org/10.7175/fe.v20i1S.1454Keywords:
Non-valvular atrial fibrillation, Novel oral anticoagulant agents, Multidisciplinary management, Therapeutic appropriatenessAbstract
Atrial fibrillation (AF) is the most prevalent form of alteration in cardiac rhythm and is associated with a high economic burden resulting from both clinical consequences and impact on patients’ quality of life. Goals of treatment include symptom control and, in the high-risk patients, the prevention of thromboembolic complications. The advent of novel oral anticoagulant agents (NOACs) has improved the management of patients with non-valvular AF (NVAF) by overcoming limitations associated with traditional oral anticoagulation drugs. NOACs are associated with a lower risk of stroke, systemic embolism, and mortality compared to vitamin K antagonists (VKAs) and with a lower risk of fatal, major, and intracranial bleeding. This supplement aims at sharing the virtuous management model of AF patients in the Local Health Unit Tuscany North-West and promoting the importance of a multidisciplinary management, which involves cardiologists and general practitioners (GPs), not only in terms of clinical outcomes, but also of therapeutic appropriateness and economic sustainability.References
Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36: 1303-9; https://doi.org/10.1016/S0735-1097(00)00886-X
Cotte FE, Chaize G, Gaudin AF, et al. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace 2016; 18: 501-7; https://doi.org/10.1093/europace/euv248
McBride D, Mattenklotz AM, Willich SN, et al. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2009; 12: 293-301; https://doi.org/10.1111/j.1524-4733.2008.00416.x
Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013; 167: 1807-24; https://doi.org/10.1016/j.ijcard.2012.12.093
Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286-92; https://doi.org/10.1136/hrt.2002.008748
Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014; 11:639-54; https://doi.org/10.1038/nrcardio.2014.118
Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-20; https://doi.org/10.2147/CLEP.S47385
Andreotti F, D’Angela D, Mancusi RL, et al. Prevalence of atrial fibrillation, treatment eligibility and consumption of oral anticoagulants in Italian Local Health Authorities: impact of non-vitamin K antagonist oral anticoagulants. G Ital Cardiol 2017; 18: 230-8; https://doi.org/doi:10.1714/2674.27400
Xu XM, Vestesson E, Paley L, et al. The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J 2018; 3: 82-91; https://doi.org/doi:10.1177/2396987317746516
Lucioni C, Mazzi S, Micieli G, et al. Valutazione economica del trattamento con alteplase di pazienti con ictus ischemico in fase acuta, con riferimento all’Italia. PharmacoEconomics - Italian Research 2010; 12: 91-103; https://doi.org/10.1007/BF03320667
Fondazione Censis, A.L.I.C.e. Italia Onlus. I costi sociali ed i bisogni assistenziali dei malati di ictus cerebrale. 2010
Il Sole 24ore Sanità. I Quaderni di Medicina. Marzo 2011
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-78; https://doi.org/10.1093/europace/euw295
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67; http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00007
Ansell J, Hirsh J, Hylek E, et al.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-98S; https://doi.org/10.1378/chest.08-0670
Makam RCP, Hoaglin DC, McManus DD, et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS One 2018; 13: e0197583; https://doi.org/10.1371/journal.pone.0197583
Casolo G, Cavirani G, Pardini M, et al. Prevalence of non valvular atrial fibrillation and Anticoagulation treatment in a large outpatient population. Analysys of the personal health records from different general practicioner groups. Eur Heart J 2016; 37: 504; https://doi.org/10.1093/eurheartj/ehw432
Occhetta E, Diotallevi P, Venegoni L, et al. I costi sanitari della Fibrillazione Atriale. Follow-up a un anno dello studio EPICARDIA. Giac 2010; 13: 232-42
Ermini G, Perrone V, Veronesi C, et al. Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study. Vasc Health Risk Manag 2017; 13: 239-46; https://doi.org/10.2147/VHRM.S136009
Cataldo N, Pegoraro V, Ripellino C, et al. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation. Recenti Prog Med 2018; 109: 113-21; https://doi.org/10.1701/2865.28904
Huisman MV, Rothman KJ, Paquette M, et al. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 2017; 69: 777-85; https://doi.org/10.1016/j.jacc.2016.11.061
Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J 2018; 39: 2975-83; https://doi.org/10.1093/eurheartj/ehy411
Maggioni AP, Dondi L, Andreotti F, et al. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. Am Heart J 2019; 220: 12-9; https://doi.org/10.1016/j.ahj.2019.10.017
National Institute for Health and Care Excellence. Costing Report: atrial Fibrillation. Implementing the NICE guideline on atrial fibrillation (CG180). Published: June 2014
Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-60; https://doi.org/10.1016/j.amjcard.2012.03.049
Liu T, Korantzopoulos P, Li L, et al. Survival benefit of new anticoagulants compared with warfarin in patients with atrial fibrillation: a meta-analysis. Int J Cardiol 2012; 156: 96-7; https://doi.org/10.1016/j.ijcard.2011.12.093
Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-91; https://doi.org/10.1161/CIRCULATIONAHA.112.115410
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 2014; 383: 955-62; https://doi.org/10.1016/S0140-6736(13)62343-0
Lip GY, Mitchell SA, Liu X, et al. Relative efficacy and safety of non-vitamin k oral anticoagulants for nonvalvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol 2016; 204: 88-94; https://doi.org/10.1016/j.ijcard.2015.11.084
Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37: 1145-53; https://doi.org/10.1093/eurheartj/ehv466
Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in us patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc 2013; 2: e000535; https://doi.org/10.1161/JAHA.113.000535
Yu AYX, Malo S, Svenson LW, et al. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study. J Am Heart Assoc 2017; 6: e007129; https://doi.org/10.1161/JAHA.117.007129
Datar M, Crivera C, Rozjabek H, et al. Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin. Am J Health Syst Pharm 2019; 76: 275-85; https://doi.org/10.1093/ajhp/zxy032
Perino AC, Fan J, Schmitt SK, et al. Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study. J Am Coll Cardiol 2017; 70: 78-86; https://doi.org/10.1016/j.jacc.2017.04.054
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
